Author:
Vaupel Peter,Multhoff Gabriele
Reference80 articles.
1. Batchelor TT, Sorensen AG, di TE, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahil DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95
2. Becker B, Multhoff G, Farkas B, Wild PJ, Landthaler M, Stolz W, Vogt T (2004) Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol 13:27–32
3. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401–410
4. Brem S, Brem H, Folkman J, Finkelstein D, Patz A (1976) Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 36:2807–2812
5. Cairns R, Papandreou I, Denko N (2006) Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 4:61–70